CA3108519A1 - Heteroaromatic nmda receptor modulators and uses thereof - Google Patents

Heteroaromatic nmda receptor modulators and uses thereof Download PDF

Info

Publication number
CA3108519A1
CA3108519A1 CA3108519A CA3108519A CA3108519A1 CA 3108519 A1 CA3108519 A1 CA 3108519A1 CA 3108519 A CA3108519 A CA 3108519A CA 3108519 A CA3108519 A CA 3108519A CA 3108519 A1 CA3108519 A1 CA 3108519A1
Authority
CA
Canada
Prior art keywords
compound
disorder
pharmaceutically acceptable
pyrrolo
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3108519A
Other languages
English (en)
French (fr)
Inventor
Robert A. Volkmann
David R. Anderson
Sam Malekiani
Timothy Piser
Gregg F. Keaney
Steven C. Leiser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Cadent Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadent Therapeutics Inc filed Critical Cadent Therapeutics Inc
Publication of CA3108519A1 publication Critical patent/CA3108519A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3108519A 2018-08-03 2019-08-02 Heteroaromatic nmda receptor modulators and uses thereof Pending CA3108519A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862714100P 2018-08-03 2018-08-03
US62/714,100 2018-08-03
PCT/US2019/044814 WO2020086136A2 (en) 2018-08-03 2019-08-02 Heteroaromatic nmda receptor modulators and uses thereof

Publications (1)

Publication Number Publication Date
CA3108519A1 true CA3108519A1 (en) 2020-04-30

Family

ID=69228330

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3108519A Pending CA3108519A1 (en) 2018-08-03 2019-08-02 Heteroaromatic nmda receptor modulators and uses thereof

Country Status (37)

Country Link
US (5) US10584131B2 (enExample)
EP (2) EP3830092B1 (enExample)
JP (1) JP7319369B2 (enExample)
KR (1) KR102797968B1 (enExample)
CN (1) CN112513047B (enExample)
AR (1) AR115905A1 (enExample)
AU (1) AU2019368147B2 (enExample)
BR (1) BR112021001967A2 (enExample)
CA (1) CA3108519A1 (enExample)
CL (1) CL2021000294A1 (enExample)
CO (1) CO2021002898A2 (enExample)
CR (1) CR20210125A (enExample)
CU (1) CU24647B1 (enExample)
CY (1) CY1126144T1 (enExample)
DK (1) DK3830092T3 (enExample)
DO (1) DOP2021000025A (enExample)
EA (1) EA202190431A1 (enExample)
EC (1) ECSP21014902A (enExample)
ES (2) ES2951872T3 (enExample)
FI (1) FI3830092T3 (enExample)
HR (1) HRP20230774T1 (enExample)
HU (1) HUE062566T2 (enExample)
IL (1) IL280474B2 (enExample)
JO (1) JOP20210020A1 (enExample)
LT (1) LT3830092T (enExample)
MA (1) MA53351B1 (enExample)
MX (1) MX2021001367A (enExample)
PE (1) PE20210948A1 (enExample)
PH (1) PH12021550242A1 (enExample)
PL (1) PL3830092T3 (enExample)
PT (1) PT3830092T (enExample)
RS (1) RS64359B1 (enExample)
SG (1) SG11202101125VA (enExample)
SI (1) SI3830092T1 (enExample)
TW (1) TWI833783B (enExample)
WO (1) WO2020086136A2 (enExample)
ZA (1) ZA202101273B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100599A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Thienopyrimidinone nmda receptor modulators and uses thereof
ES2821010T3 (es) * 2015-12-09 2021-04-23 Cadent Therapeutics Inc Moduladores heteroaromáticos del receptor NMDA y usos de los mismos
AU2017382339B2 (en) 2016-12-22 2024-02-15 Novartis Ag NMDA receptor modulators and uses thereof
PT3830092T (pt) 2018-08-03 2023-07-25 Novartis Ag Moduladores do recetor nmda heteroaromáticos e suas utilizações
WO2025019109A1 (en) * 2023-07-17 2025-01-23 Neumora Therapeutics, Inc. Modulators of nmda receptors and related products and methods

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1067079A (en) 1976-07-22 1979-11-27 Yamanouchi Pharmaceutical Co. Nitrogen-containing heterobicyclic compounds
FR2549834B1 (fr) 1983-07-25 1985-10-18 Sanofi Sa Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
US4921854A (en) 1986-12-30 1990-05-01 Egis Gyogyszergyar Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds
US5298502A (en) 1988-12-12 1994-03-29 Fmc Corporation Method and composition for photodynamic treatment and detection of tumors
AU6643694A (en) 1993-05-21 1994-12-20 Pentapharm Ag 3-(mercaptoalkyl)- or 3-(alkylthioalkyl)- pyrimidin-2,4(1h, 3h)-diones
JP2000513375A (ja) 1996-06-28 2000-10-10 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプター拮抗薬プロドラッグ
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
WO2002000629A1 (en) 2000-06-26 2002-01-03 Merck & Co., Inc. Iminopyrimidine nmda nr2b receptor antagonists
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
RU2378258C2 (ru) 2004-07-13 2010-01-10 Ф. Хоффманн-Ля Рош Аг Производные сульфонамида
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
NZ575426A (en) 2006-09-11 2010-09-30 Organon Nv Quinazolinone and isoquinolinone acetamide derivatives useful for the treatment of disorders which are influenced by modulation of the activity of the hpa axis
EP2066640B1 (en) 2006-09-11 2011-09-07 N.V. Organon 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives
JP5622393B2 (ja) 2006-12-15 2014-11-12 アブラクシスバイオサイエンス リミテッド ライアビリティー カンパニー トリアジン誘導体類及びそれらの治療応用
EP1939187A1 (en) 2006-12-20 2008-07-02 Sanofi-Aventis Substituted heteroaryl pyridopyrimidone derivatives
WO2008097538A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
JP5675341B2 (ja) 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオキソキナゾリノン誘導体
WO2008138126A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
EP2190428A4 (en) 2007-08-21 2012-02-29 Merck Sharp & Dohme HETEROCYCLIC COMPOUNDS AS DIPEPTIDYLPEPTIDASE IV HEMMER FOR TREATMENT OR PREVENTION OF DIABETES
TW200934497A (en) 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
AU2009243006B2 (en) 2008-05-01 2013-03-21 Sirtris Pharmaceuticals, Inc. Quinolines and related analogs as sirtuin modulators
CN102112475A (zh) 2008-05-29 2011-06-29 西特里斯药业公司 作为沉默调节蛋白调节剂的咪唑并吡啶和相关的类似物
EP2138494A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
BRPI0914006A2 (pt) 2008-07-03 2015-10-27 Sirtris Pharmaceuticals Inc benzimidazóis e análogos relacionados como moduladores de sirtuína
CN101628913B (zh) 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
CA2738794C (en) 2008-09-29 2016-01-05 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators
CA2747419C (en) 2009-01-12 2014-07-08 Icagen, Inc. Sulfonamide derivatives
WO2010111573A1 (en) 2009-03-27 2010-09-30 Abbott Laboratories Compounds as cannabinoid receptor ligands
EP2264035A1 (en) 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
CN102666540A (zh) 2009-10-13 2012-09-12 Msd欧斯股份有限公司 用于治疗乙酰胆碱受体相关疾病的稠合吖嗪衍生物
US9290507B2 (en) 2010-03-26 2016-03-22 Boehringer Ingelheim International Gmbh B-RAF kinase inhibitors
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
EP2593106A4 (en) 2010-07-16 2014-01-01 Univ Rockefeller ORGANIC CONNECTIONS
JP2013540145A (ja) 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤
US20120165330A1 (en) 2010-12-22 2012-06-28 Sirtris Pharmaceuticals, Inc. Quinazolinone and related analogs as sirtuin modulators
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
WO2013048928A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US8946430B2 (en) 2011-09-30 2015-02-03 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
US8993557B2 (en) 2011-09-30 2015-03-31 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
CN102336768A (zh) 2011-10-24 2012-02-01 中国科学院上海有机化学研究所 N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途
MX370976B (es) 2011-11-11 2020-01-10 Gilead Apollo Llc Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos.
EP3406252B1 (en) 2012-02-10 2020-05-13 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
WO2014066743A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2014179144A1 (en) 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
WO2014206343A1 (en) 2013-06-28 2014-12-31 Beigene, Ltd. Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
WO2015007453A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
TW201609656A (zh) 2013-09-26 2016-03-16 美涅莫辛製藥公司 Ｎｒ２ａ之ｎ-芳基甲基磺醯胺負向調節劑
PT3055315T (pt) 2013-10-11 2018-10-25 Hoffmann La Roche Tiazolopirimidonas enquanto moduladores da atividade do recetor nmda
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
CN103664877A (zh) 2013-12-25 2014-03-26 重庆医药工业研究院有限责任公司 一种喹啉衍生物、其制备方法和应用
WO2016034703A1 (en) 2014-09-05 2016-03-10 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
WO2016081649A1 (en) * 2014-11-18 2016-05-26 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto
PE20180316A1 (es) 2015-04-15 2018-02-09 Hoffmann La Roche Compuestos piridopirimidinona y su uso como moduladores del receptor de nmda
KR20180102052A (ko) 2015-10-16 2018-09-14 노오쓰웨스턴 유니버시티 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
ES2821010T3 (es) * 2015-12-09 2021-04-23 Cadent Therapeutics Inc Moduladores heteroaromáticos del receptor NMDA y usos de los mismos
WO2017100599A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Thienopyrimidinone nmda receptor modulators and uses thereof
US20170305861A1 (en) 2016-04-25 2017-10-26 Immunomet Therapeutics, Inc Heteroaryl compounds comprising nitrogen and use thereof
WO2018026371A1 (en) 2016-08-04 2018-02-08 Sunovion Pharmaceuticals Inc. Dual nav1.2/5ht2a inhibitors for treating cns disorders
AU2017382339B2 (en) 2016-12-22 2024-02-15 Novartis Ag NMDA receptor modulators and uses thereof
US10633387B2 (en) 2017-09-27 2020-04-28 Incyte Corporation Salts of TAM inhibitors
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
PT3830092T (pt) 2018-08-03 2023-07-25 Novartis Ag Moduladores do recetor nmda heteroaromáticos e suas utilizações

Also Published As

Publication number Publication date
CU20210013A7 (es) 2021-09-07
HRP20230774T1 (hr) 2023-10-27
EP4223760B1 (en) 2025-06-04
PT3830092T (pt) 2023-07-25
ECSP21014902A (es) 2021-05-31
CL2021000294A1 (es) 2021-06-18
TWI833783B (zh) 2024-03-01
SG11202101125VA (en) 2021-03-30
IL280474B2 (en) 2023-09-01
CR20210125A (es) 2021-06-30
TW202019932A (zh) 2020-06-01
US20240199617A1 (en) 2024-06-20
US10584131B2 (en) 2020-03-10
US20200039987A1 (en) 2020-02-06
ZA202101273B (en) 2023-05-31
KR102797968B1 (ko) 2025-04-22
CN112513047A (zh) 2021-03-16
MX2021001367A (es) 2021-06-23
US11542264B2 (en) 2023-01-03
HUE062566T2 (hu) 2023-11-28
KR20210039432A (ko) 2021-04-09
EP3830092A2 (en) 2021-06-09
FI3830092T3 (fi) 2023-07-21
ES2951872T3 (es) 2023-10-25
IL280474A (en) 2021-03-01
MA53351A (fr) 2022-01-12
EP4223760A1 (en) 2023-08-09
WO2020086136A2 (en) 2020-04-30
AR115905A1 (es) 2021-03-10
CU24647B1 (es) 2023-02-13
US20210403474A1 (en) 2021-12-30
EP3830092B1 (en) 2023-05-03
EA202190431A1 (ru) 2021-06-11
IL280474B1 (en) 2023-05-01
PL3830092T3 (pl) 2023-11-13
CO2021002898A2 (es) 2021-05-31
JOP20210020A1 (ar) 2021-01-25
CY1126144T1 (el) 2023-11-15
US20250034145A1 (en) 2025-01-30
RS64359B1 (sr) 2023-08-31
BR112021001967A2 (pt) 2021-04-27
PE20210948A1 (es) 2021-05-24
DK3830092T3 (en) 2023-08-07
MA53351B1 (fr) 2023-08-31
PH12021550242A1 (en) 2021-11-29
JP7319369B2 (ja) 2023-08-01
US20200131190A1 (en) 2020-04-30
JP2021534227A (ja) 2021-12-09
AU2019368147A1 (en) 2021-03-18
CN112513047B (zh) 2023-10-20
WO2020086136A3 (en) 2020-08-06
SI3830092T1 (sl) 2023-09-29
AU2019368147B2 (en) 2024-05-30
ES3039982T3 (en) 2025-10-27
DOP2021000025A (es) 2021-05-31
LT3830092T (lt) 2023-09-11
US10752633B2 (en) 2020-08-25

Similar Documents

Publication Publication Date Title
US20250034145A1 (en) Heteroaromatic nmda receptor modulators and uses thereof
CN102892288B (zh) 作为亲代谢性谷氨酸受体4(mGLuR4)变构增效剂的吡唑并吡啶化合物、吡唑并吡嗪化合物、吡唑并吡嘧啶化合物、吡唑并噻吩化合物和吡唑并噻唑化合物，组合物，以及其治疗神经学上的功能失调的方法
AU2017305240B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
CA2947976A1 (en) Combinations of nmdar modulating compounds
EA035188B1 (ru) Терапевтические соединения
WO2014078377A1 (en) Methods and compositions for treating schizophrenia
US20180325893A1 (en) Subacute administration of nmda modulators alone or in combination
EP2751095A2 (en) Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof
CN114591327B (zh) 吲哚啉哌啶脲类trpv1拮抗和mor激动双靶点药物及制备方法和应用
RU2800064C2 (ru) Гетероароматические модуляторы nmda-рецептора и их применение
HK40049118B (en) Heteroaromatic nmda receptor modulators and uses thereof
HK40049118A (en) Heteroaromatic nmda receptor modulators and uses thereof
WO2010053127A1 (ja) α1GABAA受容体またはα5GABAA受容体の調整剤
EA040862B1 (ru) Гетероароматические модуляторы nmda рецептора и их применение
US20110136853A1 (en) Ligand with a broad spectrum of pharmacological activity, a pharmaceutical composition, a medicinal agent and a method of treatment
US11014933B2 (en) Non-peptide opioid receptor modulators

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240726

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240726

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241025

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241025

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241118

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250410

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250722

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250722

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250724

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251124

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260708